Photo

Photo detail

Stories this photo appears in:

Vital Therapies Reports Q4 Results

San Diego-based Vital Therapies Inc., a company developing a cell-based therapy to help people suffering from serious liver disease, announced its fourth quarter financial results on March 19, reporting a net loss of about $14 million compared with a net loss of $10.2 million in the same quarter of 2013.

Tease photo

Vital Therapies Reports Net Loss of $10.7M for Q1

Vital Therapies Inc. reported a net loss of $10.7 million in its very first quarterly earnings report — the biotech, which is developing treatments for liver failure, began trading on the public markets April 17 with a $61.1 million IPO.

Tease photo

Vital Therapies Resets Price of Planned IPO

Vital Therapies Inc. lowered the proposed size of its planned initial public offering, according to Renaissance Capital. Vital Therapies now plans to sell 4.5 million shares at $13 to $15 per share, expecting to raise about $63 million.

Tease photo